Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy
Annals of Surgical Oncology · 2024
DOI: 10.1245/s10434-024-16005-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Surgical Oncology, 2024. Verfasst von Rachel L McCaffrey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. rl.mccaffrey@vu…. Hauptthemen laut MEDLINE: Transgender Persons, Mastectomy, Breast Neoplasms, Testosterone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Concrete, data-driven guidelines for breast cancer screening among the transgender and gender diverse (TGD) population is lacking. The present study evaluates possible associations of gender-affirming hormone therapy (GAHT) on incidental breast pathology findings in trans-masculine patients to inform decision making about breast cancer screening. Patients and Methods This was a retrospective cohort study of patients who had gender-affirming mastectomy or breast reduction at a single center from July 2019 to February 2024. A total of 865 patients met the inclusion criteria. Gender-affirming testosterone therapy and length of exposure were evaluated to seek differences in post-operative pathology findings.
Results
The median age at the time of surgery was 27 years [interquartile range (IQR) 21–30]. Most participants identified as female to male (658, 75.6%). A significant portion of the participants (688, 79.2%) were undergoing testosterone therapy at the time of surgery, with the median duration of testosterone use prior to surgery being 14 months (IQR 4–29). High risk or malignant findings were noted in pathology results for 12 of 1730 breasts (0.7%). Ordered logistic regression found that duration of testosterone therapy was not associated with increasing severity of incidental breast pathology. Additionally, patients under 25 years of age were 70% less likely to have any incidental finding on pathological evaluation than older patients [odds ratio (OR) 0.3, p < 0.01, confidence interval (CI) 0.18–0.50].
Conclusions
The present study found that patients undergoing GAHT should not be screened for breast cancer with increased frequency compared with cis-gender women. Additionally, it may be appropriate for trans women under the age of 25 with normal breast cancer risk to forego pathological breast tissue examination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. rl.mccaffrey@vumc.org.
- Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
- Oncologic Surgery, OSF Healthcare, Peoria, IL, USA.
- Vanderbilt University School of Medicine, Nashville, TN, USA.
Zitieren
APA
McCaffrey, R. L., James, A. J., Torres-Guzman, R. A., Addae, J. K., Sullivan, L. E., Dash, E., Slutsky, H., Finer, Z. R., Assi, P. E., & Al-Kassis, S. (2024). Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16005-1
Vancouver
McCaffrey RL, James AJ, Torres-Guzman RA, Addae JK, Sullivan LE, Dash E, et al. Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy. Annals of Surgical Oncology. 2024. doi:10.1245/s10434-024-16005-1
BibTeX
@article{McCaffrey2024,
author = {McCaffrey, Rachel L and James, Andrew J and Torres-Guzman, Ricardo A and Addae, Jamin K and Sullivan, Lauren E and Dash, Elianna and Slutsky, Hanna and Finer, Zoe R and Assi, Patrick E and Al-Kassis, Salam},
title = {Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy},
journal = {Annals of Surgical Oncology},
year = {2024},
doi = {10.1245/s10434-024-16005-1}
}
EUVIMED